NeuroPace (NPCE) plans to end its distribution agreement with DIXI Medical for stereo EEG products to focus on its portfolio for differentiated responsive neurostimulation systems.
The distribution agreement will wind down in Q4 and into the following quarter, NeuroPace said Wednesday in a statement.
NeuroPace maintained its 2025 revenue guidance along with long-range expectations of at least a 20% compound annual growth rate and cash flow breakeven by the end of 2027.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。